Prevalence of Amiodarone induced vortex keratopathy at Benghazi National Cardiac Centre

• Suliman M. AL-Nashad

  Department of Oph-thalmology, Faculty of Medicine, Benghazi University

  Author

• Hana A. Shaheen

  Department of Ophthal-mology, Faculty of Medicine, Benghazi University

  Author

Abstract:

Aim: to find out the prevalence of amiodarone induced vortex keratopathy among patients admitted to Benghazi cardiac center, and to grade this finding according to dose and duration of use.

Patients and Method: The descriptive cross-sectional study was conducted from 1st of January to end of February 2024 at national cardiac center and Benghazi teaching eye hospital, all patients admitted to cardiac center during six months period (from June to November 2023) and received amiodarone as part of their treatment (45) cases were included in this study.

Result: A total of 1056 cases admitted to cardiac center, 45 (4.3) cases received amiodarone

Among the 45 cases, 24 were male and 21 were female. Their age ranged from 20 to 80. 41 were Libyan, 4 were non-Libyan. 39 were from Benghazi. From the 45 cases, 24 (53%) were able to come for ophthalmic assessment. Out of 24 cases, 18(75%) had vortex keratopathy, most of them with grade II (33%).

Among those with vortex keratopathy, nine had visual complains as reduced vision, halos around light.

six out of nine who had visual complains had other findings contribute to reduced vision other than keratopathy (cataract, posterior capsular opacification, high myopia, diabetic retinopathy and its complications).

Three out of those nine patients had visual complains but no other findings except for vortex keratopathy.

Nine patients showed vortex keratopathy with no other pathology and didn't have any complains and their visual acuity was 6\6.

No other ocular complications of amiodarone use were found among our study group.

Astin, C. L. J. C. L., & Eye, A. (2001). Amiodarone keratopathy and rigid contact lens wear. 24(2), 80-82.

Cappellani, D., Bartalena, L., & Bogazzi, F. J. J. o. E. I. (2023). Short review: novel concepts in the approach to patients with amiodarone-induced thyrotoxicosis. 47(2), 275-283.

Chokesuwattanaskul, R., Shah, N., Chokesuwattanaskul, S., Liu, Z., & Thakur, R. J. T. J. o. i. i. c. r. m. (2020). Low-dose amiodarone is safe: a systematic review and meta-analysis. 11(4), 4054.

D'Amico, D. J., Kenyon, K. R., & Ruskin, J. N. J. A. o. O. (1981). Amiodarone keratopathy: drug-induced lipid storage disease. 99(2), 257-261.

Erdurmus, M., Selcoki, Y., Yagci, R., Hepsen, I. F. J. E., & Lens, C. (2008). Amiodarone-induced keratopathy: full-thickness corneal involvement. 34(2), 131-132.

Florek, J. B., Lucas, A., & Girzadas, D. (2023). Amiodarone. In StatPearls [Internet]. StatPearls Publishing.

Gašparini, D., Raljević, D., Pehar-Pejčinović, V., Klarica Gembić, T., Peršić, V., & Turk Wensveen, T. J. F. i. c. m. (2023). When amiodarone-induced thyroiditis meets cardiomyopathy with excessive trabeculation: a case report. 10, 1212965.

Hamilton, D., Nandkeolyar, S., Lan, H., Desai, P., Evans, J., Hauschild, C., Choksi, D., Abudayyeh, I., Contractor, T., & Hilliard, A. J. A. J. o. C. D. (2020). Amiodarone: a comprehensive guide for clinicians. 20, 549-558.

Hollander, D. A., & Aldave, A. J. J. C. o. i. o. (2004). Drug-induced corneal complications. 15(6), 541-548.

Ingram, D., Jaggarao, N., & Chamberlain, D. J. B. J. o. O. (1982). Ocular changes resulting from therapy with amiodarone. 66(10), 676-679.

Koh, S., Hamano, T., Ichii, M., Yatsui, K., Maeda, N., & Nishida, K. J. C. (2019). Transient cornea verticillata of unknown etiology: a case report. 38(5), e16-e17.

Lamont, M., Madge, S. N., Quinn, A., Anderson, D. F., & Habib, N. J. O. (2010). Vortex Keratopathy and Fabry Disease: A Case Series Highlighting the Role of the Optometrist. 11(3), 107-110.

Mahajan, D., Verma, A., & Sharma, R. J. A. J. o. O. (2020). Amiodarone-induced vortex keratopathy at a low maintenance dose. 17(2), 170-172.

Mäntyjärvi, M., Tuppurainen, K., & Ikäheimo, K. J. S. o. o. (1998). Ocular side effects of amiodarone. 42(4), 360-366.

Maruf, S., Nath, P., Islam, M. R., Aktar, F., Anuwarul, A., Mondal, D., & Basher, A. J. P. n. t. d. (2018). Corneal complications following post kala-azar dermal leishmaniasis treatment. 12(9), e0006781.

Orlando, R. G., Dangel, M. E., & Schaal, S. F. J. O. (1984). Clinical experience and grading of amiodarone keratopathy. 91(10), 1184-1187.

Sahyoun, J.-Y., Sabeti, S., & Robert, M.-C. J. B. o. o. (2022). Drug-induced corneal deposits: an up-to-date review. 7(1), e000943.

Shah, G. K., Cantrill, H. L., & Holland, E. J. (1995). Vortex keratopathy associated with atovaquone. American journal of ophthalmology, 120(5), 669-671.

• PDF

Copyright (c) 2024 Hana shaheen (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright of the articles Published by Almukhtar Journal of Science (MJSc) is retained by the author(s), who grant MJSc a license to publish the article. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors and cite MJSc as the original publisher. Also, they accept the article remains published by the MJSc website (except in the occasion of a retraction of the article).